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as liver, spleen, bone marrow, or lymph nodes. The clinical features are highly variable depending on impairment of the involved organ systems.
It often raises diagnostic challenges. Here we report a case of a 78-year-old patient with mast cell leukemia. The literature is reviewed regarding
the diagnosis and updated management of this rare disease.
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Systemic mastocytosis (SM) is a heterogeneous clonal
disorder, characterized by abnormal mast cell infiltration in
extracutaneous organs. It is classified into a subcategory
under myeloproliferative neoplasm in the 2008 revision of
the World Health Organization classification.1 The clinical
presentation varies, depending on impaired organ function
resulting from accumulation of these clonally derived mast
cells in different tissues including bone marrow, skin,
gastrointestinal tract, liver, spleen, and lymph nodes. In
Taiwan, SM is an extremely rare disease with limited clinical
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reviewed regarding the diagnosis and updated management
of this rare disease.2. Case report
A 78-year-old male patient presented with a 3-month his-
tory of fever and thrombocytopenia. He had a past history of
coronary artery disease, chronic obstructive pulmonary dis-
ease, and duodenal ulcer. On admission, physical examination
revealed jaundice, splenomegaly, marked edema and multiple
petechiae over lower limbs, and no skin rashes. Laboratory
examinations showed a leukocyte count of 12.2  109/L with
75% segmented neutrophil and 9% lymphocytes in differen-
tial; hemoglobin level of 9.4 g/dL and platelet count of
15.0  109/L. Total bilirubin level was 2.48 mg/dL (normal
range 0.2e1.6 mg/dL). Serum albumin level was 2.7 g/dL
(normal range 3.7e5.3 g/dL). The LDH level was 389 U/L
(normal range 130e250 U/L). Infiltration in bilateral lowerociation. All rights reserved.
Fig. 1. (A) Bone marrow cytology (Wright stain, 1000 ), profuse infiltration of blast-form cells with more than half of the blasts containing metachromic granules
or vacuoles in the cytoplasm. (B) Bone marrow biopsy (hematoxylin and eosin stain, 100 ), profuse infiltration of monotonous malignant cells. (C) Bone marrow
biopsy (tryptase stain, 200 ). (D) Bone marrow biopsy (CD 25 stain, 200 ).
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raphy (CT) of the abdomen revealed splenomegaly, pleural
thickness, and increased infiltration and consolidation over
bilateral lower lung fields. Immature blast-like cells with
cytoplasmic vacuoles were observed in peripheral blood
smear. Bone marrow aspirate showed diffuse infiltration of
blast-like cells around 75%, with more than half of blasts
containing metachromatic granules (appearing a different
color after staining by basic dye methylene blue of Wright's
stain) or vacuoles in the cytoplasm (Fig. 1A and B). The
granules occupied nearly the whole cytoplasm suggestive for
mast cell lineage. Surface marker study in bone marrow bi-
opsy showed positive staining for tryptase, CD117, and CD25
in the majority of the cells, while negative staining for lyso-
zyme (Fig. 1C and D). The whole picture is compatible withFig. 2. Sequencing results of the PCR product for c-Kit shows 2447systemic mastoytosis and MCL was diagnosed based on >20%
blasts in the marrow aspirate. Chromosome analysis of bone
marrow cells noted the presence of trisomy 8. Molecular
analysis of the marrow cells confirmed the presence of
KITD816V mutation (Fig. 2), whereas a study of the
JAK2V617F mutation showed negative results.
During hospitalization, the patient had been weak and
confined to bed all day. With the use of antibiotics, his fever
subsided in the 3rd week of hospitalization. However, gener-
alized edema deteriorated owing to malnutrition and hypo-
albuminemia status and respiratory distress persisted.
Treatment with imatinib mesylate was tried initially
without clinical improvement in thrombocytopenia and jaun-
dice. Abdominal pain and vomiting developed later with
elevated levels of amylase (322 U/L; normal range, <180 U/L)A > T pathogenic variation at codon 816 of exon 17 (D816V).
448 D.-Y. Lu et al. / Journal of the Chinese Medical Association 77 (2014) 446e449and lipase (837 U/L; normal range, <180 U/L). Acute
pancreatitis was diagnosed. With the detection of the
KITD816V mutation, compassionate use of another multi-
target protein kinase inhibitor, midostaurin (PKC412), had
been tried for 1 week. Fever relapsed again and persisted, and
the patient's clinical condition gradually deteriorated. He
finally died of sepsis and disseminated intravascular coagula-
tion 3 weeks after the diagnosis of the malignancy.
3. Discussion
Mastocytosis is classified into three categories according to
the 2008 World Health Organization classification: (1) cuta-
neous mastocytosis, in which mast cell infiltration is confined
to the skin; (2) SM, in which at least one extracutaneous organ
is involved; and (3) extracutaneous mast cell neoplasm, either
as malignant mast cell sarcoma or as benign extracutaneous
mastocytoma.2
SM can be further categorized into four subtypes: (1)
indolent SM, with maculopapular skin lesions but no organ
dysfunction; (2) aggressive SM (ASM), defined by patholog-
ical mast cells infiltrating bone marrow, liver, spleen, gastro-
intestinal tract and the skeletal system; (3) SM with an
associated clonal hematological nonmast cell lineage disease,
in which the nature of the associated hematological disorder
dictates treatment and prognosis; and (4) MCL, with a high
percentage of neoplastic mast cells in bone marrow aspirate
(>20%) and peripheral blood, resulting in multiorgan failure
and a fatal outcome.2
KITD816V mutation was detected in this patient. SM is
frequently associated with the gain-of-function mutation in the
gene encoding the tyrosine kinase KIT. The most frequently
detected single-point mutation in neoplastic mast cells is
KITD816V, which disrupts the hydrogen bond between resi-
dues D816 and N819, leading to KIT auto-phosphorylation
and uncontrolled proliferation.3,4 In a recently reported se-
ries including 342 cases of SM, the mutation rate of
KITD816V was 78% in indolent SM, 82% in ASM, and 60%
in SM with an associated clonal hematological nonmast cell
lineage disease.5
Although serum tryptase level was not determined, the
tissue infiltration of mast cells combined with the aberrant
expression of CD25 in mast cells and the presence of D816V
mutation fulfilled the diagnostic criteria of mastocytosis.
Moreover, profuse infiltration of immature mast cells (>20%)
in the bone marrow aspiration smear was observed in this
patient, supporting categorization of the diagnosis into MCL.
MCLis an extremely rare disorder, accounting for <1% of
patients with SM.
The clinical course of SM varies, from slowly progressive
to rapidly fatal. Individualized treatment regimen is required.
Generally speaking, SM remains incurable, and therapy is
primarily palliative. In patients with ASM, cytoreductive
therapy is required. Current first-line treatment options
include interferon and 2-chlorodeoxyadenosine (2CdA).
These agents may temporarily stop disease progression butdo not have long-lasting effects. Owing to the rarity of MCL,
treatment of this disease is mainly based on the experience
from ASM.
Although the mutant KITD816V kinase can be frequently
detected in patients with SM,6 clinical response to treatment
with tyrosine kinase inhibitor has been disappointing. Imatinib
is the first tyrosine kinase inhibitor used to treat SM. It inhibits
in vitro the growth of cells with wild type KIT protein or with
KITV560G mutant, but not the cells with KITD816V mutant.6
Using imatinib to treat 24 patients of advanced SM, an Italian
study reported that only one patient achieved complete
remission and four patients achieved partial remission. None
of the responders had the KITD816V mutation.7 Imatinib has
been approved by the United States Food and Drug Admin-
istration for treating adult patients who have ASM without the
KITD816V mutation or with unknown KIT mutational status.
The median survival in MCL is relatively short.5 Our case
died of the disease shortly after diagnosis. First-line therapy
with interferon was skipped because the medicine would not
be reimbursed by the National Health Insurance and was not
available otherwise. Our patient had received treatment with
imatinib for 1 week prior to the detection of the KITD816V
mutation. Consistent with previous reports, no clinical
improvement was observed. The patient had jaundice on
admission and developed acute pancreatitis during hospitali-
zation. The pancreatitis was probably related to systemic
organ infiltration by mast cells.
Midostaurin (PKC412) is an oral multitargeted kinase in-
hibitor, capable of inhibiting KIT, FLT-3, and PDGFR.8 It can
suppress the growth of human mast cells harboring either
KITD816V mutant or wild-type KIT. In a Phase 2 trial,
Midostaurin demonstrated efficacy in patients with ASM or
MCL, with or without the KITD816V mutation. A positive
correlation was observed between the presence of KITD816V
mutation and major response (p ¼ 0.0095).9 Midostaurin had
been tried in our patient without clinical response, probably
related to the far advanced disease status precluding enough
time of medication with this novel agent.
In conclusion, we encountered a patient of MCL, who
pursued a rapidly fatal clinical course despite the trial of
imatinib and midostaurin. Although extremely rare, systemic
mastocytosis can challenge hematologists in the aspects of
diagnosis and management. Early diagnosis of the disease and
prompt initiation of novel active agents probably could
improve the prognosis.References
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